Interactions of conjugate vaccines and co-administered vaccines

Findlow, Helen; Borrow, Raymond

doi:10.1080/21645515.2015.1091908

Cited by 51 publications

(38 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the production, coverage, safety and immunogenicity of CPS conjugate vaccines have been well established, they show several limitations, including [95][96][97][98] (1) their limited usability in the low-income countries due to the high cost, 96 (2) potential immune interference with other type of conjugate vaccines, 99 (3) the possibility of serotype replacement and switching following the vaccination, 37,100-102 and (4) an increase in the occurrence of the unencapsulated GBS. [103][104][105] Therefore, a structurally conserved protein antigen-based vaccine against GBS has been investigated as alternative vaccines.…”

Section: Surface Anchoring Adhesinsmentioning

confidence: 99%

Progress toward a group B streptococcal vaccine

Song

Lim

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of severe invasive disease in neonate, elderly, and immunocompromised patients worldwide. Despite recent advances in the diagnosis and intrapartum antibiotic prophylaxis (IAP) of GBS infections, it remains one of the most common causes of neonatal morbidity and mortality, causing serious infections. Furthermore, recent studies reported an increasing number of GBS infections in pregnant women and elderly. Although IAP is effective, it has several limitations, including increasing antimicrobial resistance and late GBS infection after negative antenatal screening. Maternal immunization is the most promising and effective countermeasure against GBS infection in neonates. However, no vaccine is available to date, but two types of vaccines, protein subunit and capsular polysaccharide conjugate vaccines, were investigated in clinical trials. Here, we provide an overview of the GBS vaccine development status and recent advances in the development of immunoassays to evaluate the GBS vaccine clinical efficacy.

show abstract

Section: Surface Anchoring Adhesinsmentioning

confidence: 99%

Progress toward a group B streptococcal vaccine

Song

Lim

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Previous studies examining the effect of immunization on CRE in preterm infants did not use pneumococcal vaccine in combination with diphtheria-tetanus-acellular pertussis immunization 18,19 . Overall, the literature reports comparable or increased antibody response to combined vaccines, including with 10-valent pneumococcal conjugate vaccine or 7-valent pneumococcal conjugate vaccine 32 . Side effects in pediatric studies such as fever and irritability are reported as similar or slightly increased with combined vaccines, while remaining within clinically acceptable ranges 33 .…”

Section: Discussionmentioning

confidence: 97%

Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study

Jmaa

Hernández

Sutherland

et al. 2017

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

The first immunization of infants born < 32 weeks was associated with an increase in CRP. Ibuprofen treatment significantly attenuated the variation (Δ) in CRE following first immunization in these infants but the current study could not demonstrate an impact on CRP and PgE2 levels. The impact of anti-inflammatory treatment on antigenicity must be evaluated before their clinical use aiming at reducing CRE after immunization in preterm infants.

show abstract

“…Several other studies showed that Nimenrix can be safely and efficiently coadministered with many vaccines such as diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus and H. influenzae type b conjugate vaccine. These are (DTaP-IPV-HBV/Hib, Infanrix-hexa), Priorix-Tetra (measles, mumps, rubella, varicella vaccine) and 10-valent pneumococcal conjugate vaccine (Synflorix) [33,34].…”

Section: Discussionmentioning

confidence: 99%

Synergistic Effect of Coadministration of <em>Haemophilus influenzae</em> and <em>Neisseria meningitidis</em> Vaccines on Immune Responses to Meningitis in Mouse Model

Abdeltawab

et al. 2017

Preprint

View full text Add to dashboard Cite

Meningitis is a severe disease associated with death in children under five with highest rates of infections under age of one. Vaccines for Neisseria meningitides and Haemophilus influenza are used to prevent the main causative agents of meningitis. Administration of H. influenzae type b (Hib) vaccine is recommended at 2, 4 and 6 months with a booster dose at 18 months. N. meningitidis has two commercially available vaccines, the pure polysaccharide is recommended at 24 months meanwhile the protein-conjugated vaccines at 12 months. We sought in this study to examine if coadministering the vaccines for the two main meningitis causing bacteria might be synergistic as a preliminary step towards the possibility of shuffling immunization schedule. So, we coadministered Hib vaccine with commercially available vaccines either quadrate (ACWY) polysaccharide meningococcal (Men) or conjugated meningococcal (Nim) vaccines in Balb/C mice (n = 6/group) and compared to each vaccine administered separately and controls. Thirty-five days post immunization, we measured specific antibodies titers. Hib vaccine increased Men antibody titers significantly for serotypes Y and W. When Hib vaccine was coadministrated with Nim, antibody titer for Y, W and A significantly increased. For serotype C, there was no significant difference in antibody titers among immunized groups. As for effect of meningococcal vaccines on Hib, Men significantly increased Hib antibody titers while Nim had no effect. Collectively, our data suggested that coadministration of Hib and Men or Nim vaccines was safe and had synergistic effect on immune responses elicited to both vaccines. Further studies are needed before immunization schedule modifications. Such immunization schedule recommendation should provide better protection against this life-threatening disease in young children.

show abstract

Interactions of conjugate vaccines and co-administered vaccines

Cited by 51 publications

References 13 publications

Progress toward a group B streptococcal vaccine

Progress toward a group B streptococcal vaccine

Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study

Synergistic Effect of Coadministration of <em>Haemophilus influenzae</em> and <em>Neisseria meningitidis</em> Vaccines on Immune Responses to Meningitis in Mouse Model

Contact Info

Product

Resources

About